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| INTRODUC TI ON
Neurotrophins are growth factors with high homology in their sequence and structure. Neurotrophins are involved in neural activities, such as synapse formation, synapse modulation and neuronal plasticity. 1, 2 Neurotrophin actions depend on the activation of the tropomyosin receptor kinase (Trk) family and the low-affinity p75
receptor. 3 The neurotrophins brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5) participate in synapse efficacy, and their final effects depend on the neuronal type, temporal timing of the physiological response and maturity of the experimental organism. [4] [5] [6] [7] In the neuromuscular plate, these neurotrophins potentiate synaptic activity [8] [9] [10] ; additionally, they modulate excitatory synaptic transmission in the nervous system through the activation of TrkB receptors. 9, [11] [12] [13] TrkB receptors in turn trigger the MAPK, PI3K, and PLC-γ signaling pathways in glutamatergic synapses. [14] [15] [16] [17] In the striatum, BDNF, NT-4/5, and TrkB receptors are present. 18 The striatum receives trophic support from BDNF, which is synthesized in the cortex and transported to the striatum through the corticostriatal pathway. 19 Less is known about the cells that synthesize NT-4/5, but BDNF and NT-4/5 are differentially expressed throughout striatal postnatal development. While BDNF expression decreases, NT-4/5 increases in the first postnatal month in mice, 20 suggesting that NT-4/5 may play a major physiological role during adulthood. We have previously shown that BDNF and NT-4/5 independently potentiate corticostriatal transmission to different degrees, 21 but it is unknown how both neurotrophins affect transmission when they are coexpressed.
What is the purpose of the coexistence of two neurotrophins that ac- TrkB.T2, and TrkB.T-Shc. 12 Then, the expression levels of TrkB-FL, TrkB.
T1, and p-TrkB in striatal tissue and a cell system were evaluated after neurotrophin treatment. Our experiments show, for the first time, that NT-4/5 inhibits the effects of BDNF by modifying the expression levels of the TrkB.T1 and TrkB-FL isoforms.
| ME THODS
Male C57BL/6 mice (ENVIGO, México) 35 days old at the beginning of the experiments were used. The mice were housed in groups of five in Plexiglas boxes at room temperature (24-26°C) under a 12:12 hours light/dark cycle with free access to food and water. The experimental procedures followed the national and international regulations for the care and use of experimental animals and were approved by the local bioethics committee.
| Reagents
BDNF and NT-4/5 (PreProtech Inc, Rocky Hill, NJ, USA) were used in a concentration of 50 ng/mL (neurotrophins were reconstituted in water 1.0 mg/mL and diluted in phosphates Buffer, 0.1 mol/L, pH 7.4, following vendor instructions), and the rest of reagents were purchased from SIGMA-Aldrich Co. LLC (St Louis, MO) unless otherwise stated.
| Preparation of striatal slices for electrophysiological recordings
The mice were anesthetized with halothane; then, they were decapitated, and their brains removed and placed in ice-cold (4°C) and oxy- 
| Electrophysiological recordings
The electrophysiological experiments were performed in a recording chamber perfused with physiological saline (in mmol/L; 125 
| Stimulation protocol
A paired-pulse protocol was used to analyze the pre-or postsynaptic mechanisms of the neurotrophic effect. Then, a pair of stimuli (S1, S2) with the same duration and intensity was administered through the bipolar electrode with 30-50 ms intervals. The population spikes were recorded for 10 minutes before neurotrophin treatment. Data were digitized, stored and analyzed offline with the aid of Microcal Origin, 9.1 (Microcal Origin Lab Corp., Northampton, MA, USA).
| Western blot analysis
To evaluate TrkB receptors and PLC signaling, cerebral slices containing the striatum were incubated at RT and bubbled (95% O 2 -5% (1:1000), PLC-γ1 (1:1000), phospho-Tyr759-PLC-γ2 (1:1000), PLC-γ2 
| Analysis of cells extracts by electrophoresis and Western blotting
After cell transfection and neurotrophin treatment, cell cultures were washed twice with PBS, scraped, lysed in 
| Data analysis
Data were analyzed with Sigma Plot 12.3 (Systat Software, Inc, San
Jose, CA, USA) using parametric or nonparametric one-way ANOVA, Data followed by post hoc analysis. Significance was set at P < 0.05, and the results are expressed as the mean ±SEM, unless otherwise specified.
| RE SULTS

| NT-4/5 blocks BDNF synaptic augmentation of corticostriatal synaptic transmission
With a stable recording, either BDNF or NT-4/5 was applied to the recording bath. Figure 1A and B shows that BDNF increased spike amplitude in response to S1 compared to the control, as we previously reported. 21 However, when NT-4/5 was administered in the presence of BDNF, the spike amplitude significantly decreased ( Figure 1C ). This effect implies that NT-4/5 antagonizes the effect of BDNF on corticostriatal transmission. PPR analysis (S2/S1) did not F I G U R E 2 Signaling pathways associated with BDNF effects. A, Summary of the time course of the population spike amplitude in the presence of the inhibitors of Trk receptor, PI3K, and MAPK K252a (200 nmol/L), LY294002 (5 µmol/L), and U0126 (100 nmol/L), all dissolved in 0.05%-0.1% DMSO were followed by BDNF. Each experimental condition was normalized to the inhibitor effect. These inhibitors prevented the amplitude increase produced by BDNF. B, Average of the spike amplitude in the presence of inhibitors plus BDNF are displayed in the bars. C, PPR analysis of inhibitors used in A showed no differences. D, Time course of the population spike amplitude in the presence of the PLC-γ inhibitor. This inhibitor alone increases the population spike compared to control and BDNF significantly reduced this effect on synaptic amplitude. E, Representative traces of population spikes in each condition. F, Averages of the spike amplitude in control, in the presence of U73122 and U73122 → BDNF is displayed in the bars (F 2,11 = 17.224, P < 0.001, ANOVA with a post hoc Holm Sidakmethod). G, PPR analysis showed significant differences in the PPR of U73122 vs, control and U73122→BDNF (F 2,14 = 10.396, P = 0.002, ANOVA with a post hoc Holm Sidak-method). *P < 0.05 (n = 6; Mean ± SE) show significant differences, suggesting that both neurotrophins modulate corticostriatal transmission via postsynaptic mechanisms ( Figure 1D ).
| NT-4/5 modulation on corticostriatal transmission was not modified by BDNF
Next, we sought to evaluate whether BDNF was able to antagonize calcium concentration in the recording solution, the U73122-dependent increase in the spike amplitude was eliminated, demonstrating that an extracellular calcium-activated mechanism was responsible for this U73122 effect (data not shown).
| Signaling pathways involved in the neuromodulation of NT-4/5 in corticostriatal synapses
In the evaluation of the signaling pathways involved in the NT-4/5 modulation of corticostriatal synapses, blocking of the Trk receptors and the PI3K, or MAPK pathways prevented NT-4/5 modulatory actions on corticostriatal synapses, similar to the effects seen with BDNF. Figure 3A -C summarizes the effect of the Trk receptor inhibitor as well as the PI3K and MAPK signaling pathways. As described above the PLC inhibitor increases the synaptic spike amplitude, the further administration of NT-4/5 did not modify the U73122 effect on spike amplitude in the corticostriatal synapse ( Figure 3D-F) . PPR (S2/S1) analysis did not show a significant difference among the experimental conditions ( Figure 3G ).
| NT-4/5 antagonism of BDNF is independent from PLC activation
Given that PLC-γ activation by BDNF or NT-4/5 is associated with glutamate release in cortical neurons 22 and since the PLC inhibitor potentiates corticostriatal transmission, the following experiments investigated whether NT-4/5 uses PLC signaling activation to antagonize the effect of BDNF. In experiments where U73122
followed BDNF administration, U73122 did not modify the BDNF effect. Moreover, the spike amplitude was significantly reduced when NT-4/5 followed BDNF → U73122 incubation ( Figure 4A-C) .
These data showed that the antagonism exhibited by NT-4/5 on the 
The blots obtained for p-PLC-γ1
Tyr783 and p-PLC-γ2 Y759 at 30´ did not show differences among the treatments ( Figure 5E , rows 3-6, and H).
| NT-4/5 inhibits BDNF effect by downregulating TrkB-FL and upregulating TrkB-T.1
The 
| D ISCUSS I ON
The main finding in our study was the discovery that NT-4/5 inhibits BDNF activity by stimulating the TrkB.T1 isoform and downregulating the TrkB-FL receptor. Previously, we showed that BDNF and NT-4/5 potentiate corticostriatal transmission to different degrees. 21 Since both neurotrophins are present in the striatum and both target striatal medium spiny neurons, we questioned whether their effects were additive, no additive, or occlusive. In particular, we evaluated the physiological relevance of the sequential administra- TrkB.T1 and downregulates TrkB-FL. TrkB.T1 was evaluated in COS-7 cells because it is the predominant isoform in the adult brain 42, 43 ; furthermore, it regulates TrkB-FL function, 44 and its main role is to inhibit TrkB-FL signaling by forming inactive heterodimers with the TrkB-FL receptor 36 or by sequestering neurotrophins and preventing their binding to TrkB-FL. 34 
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